Retatrutide

What is Retatrutide?

Retatrutide is a 39-amino-acid synthetic peptide developed as a unimolecular triple agonist of GLP-1, GIP, and glucagon receptors. It is one of the most studied next-generation incretin-class molecules and is currently progressing through late-stage clinical trials (Phase III as of 2025-2026) for obesity and metabolic disease under the Eli Lilly designation LY3437943. Research-grade retatrutide is used in preclinical receptor pharmacology and metabolic models.

Mechanism of action (preclinical evidence)

Retatrutide simultaneously activates three Gαs-coupled GPCRs: the GLP-1 receptor (canonical incretin pathway), the GIP receptor (gastric inhibitory polypeptide pathway), and the glucagon receptor (hepatic glucose output and energy expenditure). The triple-agonist design aims to combine the appetite-suppressing effects of GLP-1, the additional metabolic effects of GIP, and glucagon-mediated increases in energy expenditure — a profile that single-receptor agonists cannot achieve.

Research applications

• Multi-receptor agonist receptor binding and selectivity studies
• Adipocyte and hepatic metabolic models
• Comparative pharmacology vs single-agonists (semaglutide, tirzepatide)
• Energy expenditure and food intake rodent models
• GLP-1/GIP/glucagon signaling pathway research

Storage and handling

Store lyophilised retatrutide at -20 °C in a sealed, desiccant-protected vial. Once reconstituted, large peptides like retatrutide are particularly susceptible to surface adsorption and freeze-thaw degradation; aliquot in low-protein-binding tubes and minimize repeated thawing.

Regulatory status

Retatrutide is currently an investigational drug in clinical trials. It is NOT approved by FDA, EMA, or any other regulator for any indication as of 2026. Supplied strictly for laboratory research; not for human or veterinary use.